Gregory Norden - Zoetis Independent Director

ZTS Stock  USD 169.21  0.70  0.42%   

Director

Mr. Gregory Norden is Independent Director of the Company. Prior to his role as Chief Financial Officer of Wyeth, Mr. Norden held various senior positions with Wyeth Pharmaceuticals and American Home Products. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen Co. Mr. Norden currently serves on the boards of Entasis Therapeutics, a leader in the discovery and development of breakthrough antiinfective products NanoString Technologies, a provider of life science tools for translational research and development of molecular diagnostic products Royalty Pharma, a leader in the acquisition of revenueproducing intellectual property and Univision, the leading media company serving Hispanic America. Mr. Norden is a former director of Welch Allyn, where he served until 2015 Lumara Health, where he served until 2014 and Human Genome Sciences, Inc., where he served until 2012. In addition, Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate finance advisory services since 2013.
Age 62
Tenure 11 years
Address 10 Sylvan Way, Parsippany, NJ, United States, 07054
Phone973 822 7000
Webhttps://www.zoetis.com
Norden’s background in finance and experience as a senior executive in the global healthcare and pharmaceutical industries, along with his public company board experience, make him a valuable member of our Board.

Zoetis Management Efficiency

The company has Return on Asset of 0.1315 % which means that on every $100 spent on assets, it made $0.1315 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4982 %, implying that it generated $0.4982 on every 100 dollars invested. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to gain to 0.17 in 2024, whereas Return On Capital Employed is likely to drop 0.15 in 2024. At this time, Zoetis' Intangible Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 336.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.6 B in 2024.
The company has 6.8 B in debt with debt to equity (D/E) ratio of 1.48, which is OK given its current industry classification. Zoetis Inc has a current ratio of 2.14, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Zoetis until it has trouble settling it off, either with new capital or with free cash flow. So, Zoetis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zoetis Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zoetis to invest in growth at high rates of return. When we think about Zoetis' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Harrington BischofOld Republic International
85
Gary PolinerMGIC Investment Corp
67
Mark ZandiMGIC Investment Corp
61
Raymond AnstissFidus Investment Corp
50
Lisa CaldwellOld Republic International
60
Edward TuneFidus Investment Corp
N/A
James HellauerOld Republic International
77
Donald NicolaisenMGIC Investment Corp
70
Jodeen KozlakMGIC Investment Corp
57
Daniel ArrigoniMGIC Investment Corp
70
Charles TittertonOld Republic International
76
Donald CourtneyEncore Wire
87
Charles KovaleskiOld Republic International
72
Peter McNittOld Republic International
66
John MazzarinoFidus Investment Corp
63
Glenn ReedOld Republic International
68
John WilsonEncore Wire
75
Chuck ChaplinMGIC Investment Corp
63
John DixonOld Republic International
81
Fredricka TaubitzOld Republic International
77
William WaltzQuanex Building Products
56
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis Inc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 12100 people. Zoetis Inc (ZTS) is traded on New York Stock Exchange in USA. It is located in 10 Sylvan Way, Parsippany, NJ, United States, 07054 and employs 14,100 people. Zoetis is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Zoetis Inc Leadership Team

Elected by the shareholders, the Zoetis' board of directors comprises two types of representatives: Zoetis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zoetis. The board's role is to monitor Zoetis' management team and ensure that shareholders' interests are well served. Zoetis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zoetis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Steven Frank, Vice Relations
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
Wafaa Mamilli, Executive Vice President and Chief Information and Digital Officer
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations
Linda Rhodes, Independent Director
Timothy Bettington, Executive Vice President and President U.S. Operations
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sherry Pudloski, Executive Vice President - Corporate Affairs and Communications
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
William Price, VP Officer
Catherine Knupp, Executive Vice President, President - Research and Development
Jeannette Astorga, Executive Officer
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Antoinette Leatherberry, Independent Director
Nick Ashton, Executive Supply
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Wetteny Joseph, Chief Financial Officer, Executive Vice President, Head of Business Development
Sandra Beaty, Executive Vice President - Corporate Affairs
Robert Kelly, Executive Vice President and President International Operations
J McFarland, Executive Vice President and Chief Medical Officer
Robert Polzer, Executive Vice President and Presidentident of Research and Development
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Abhay Nayak, Executive Vice President Head of Strategy and Accelerated Growth Businesses
Juan Alaix, Chief Executive Officer, Director

Zoetis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zoetis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Zoetis Investors Sentiment

The influence of Zoetis' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Zoetis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Zoetis' public news can be used to forecast risks associated with an investment in Zoetis. The trend in average sentiment can be used to explain how an investor holding Zoetis can time the market purely based on public headlines and social activities around Zoetis Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Zoetis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Zoetis' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Zoetis' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Zoetis.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zoetis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zoetis' short interest history, or implied volatility extrapolated from Zoetis options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Zoetis Inc is a strong investment it is important to analyze Zoetis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zoetis' future performance. For an informed investment choice regarding Zoetis Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zoetis Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Zoetis Stock analysis

When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Is Zoetis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zoetis. If investors know Zoetis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zoetis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.164
Dividend Share
1.5
Earnings Share
5.07
Revenue Per Share
18.527
Quarterly Revenue Growth
0.085
The market value of Zoetis Inc is measured differently than its book value, which is the value of Zoetis that is recorded on the company's balance sheet. Investors also form their own opinion of Zoetis' value that differs from its market value or its book value, called intrinsic value, which is Zoetis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zoetis' market value can be influenced by many factors that don't directly affect Zoetis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zoetis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zoetis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zoetis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.